Antiplatelets/dabigatran-etexilate/ibrutinib

Antiplatelets/dabigatran-etexilate/ibrutinib Reactions 1704, p40 - 2 Jun 2018 Antiplatelets/dabigatran-etexilate/ ibrutinib Haematospermia and haematuria: 2 case reports In a retrospective analysis involving 74 patients, two patients [ages and sexes not stated] were described, one of the two patients developed haematospermia during treatment with ibrutinib and unspecified antiplatelet drugs, while the second patient developed haematuria during treatment with dabigatran etexilate [dabigatran] and ibrutinib [routes, dosages and durations of treatments to reactions onsets not stated, not all indications stated]. One of the two patients started receiving ibrutinib along with unspecified antiplatelet drugs, and the second patient started receiving dabigatran etexilate along with ibrutinib for atrial fibrillation. However, the patient who was receiving ibrutinib with unspecified antiplatelet drugs, developed transient grade II bleeding (haematospermia). Consequently, the patient discontinued the antiplatelet therapy, but continued ibrutinib without any further complications. The second patient who was receiving dabigatran etexilate with ibrutinib, developed grade II bleeding (haematuria). Thereafter, the patient’s dabigatran-etexilate therapy was discontinued, but ibrutinib was continued without any further complications [not all outcomes stated]. Author comment: "The drug [Ibrutinib] is associated with 6–10% risk of atrial fibrillation and an increased risk of bleeding. From the 12 patients receiving concomitant BTK inhibitors and either antiplatelet drugs or anticoagulation there were 2 cases of grade 2 bleeding." Mihailescu L, et al. The plymouth experience of bleeding complications associated with concomitant treatment with BTK inhibitors and anticoagulants or antiplatelet drugs. British Journal of Haematology 181 (Suppl. 1): 175 (plus poster) abstr. BSH18-EP-033, Apr 2018. Available from: URL: http://doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323365 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antiplatelets/dabigatran-etexilate/ibrutinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/antiplatelets-dabigatran-etexilate-ibrutinib-ZHAU2GduLH
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46683-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p40 - 2 Jun 2018 Antiplatelets/dabigatran-etexilate/ ibrutinib Haematospermia and haematuria: 2 case reports In a retrospective analysis involving 74 patients, two patients [ages and sexes not stated] were described, one of the two patients developed haematospermia during treatment with ibrutinib and unspecified antiplatelet drugs, while the second patient developed haematuria during treatment with dabigatran etexilate [dabigatran] and ibrutinib [routes, dosages and durations of treatments to reactions onsets not stated, not all indications stated]. One of the two patients started receiving ibrutinib along with unspecified antiplatelet drugs, and the second patient started receiving dabigatran etexilate along with ibrutinib for atrial fibrillation. However, the patient who was receiving ibrutinib with unspecified antiplatelet drugs, developed transient grade II bleeding (haematospermia). Consequently, the patient discontinued the antiplatelet therapy, but continued ibrutinib without any further complications. The second patient who was receiving dabigatran etexilate with ibrutinib, developed grade II bleeding (haematuria). Thereafter, the patient’s dabigatran-etexilate therapy was discontinued, but ibrutinib was continued without any further complications [not all outcomes stated]. Author comment: "The drug [Ibrutinib] is associated with 6–10% risk of atrial fibrillation and an increased risk of bleeding. From the 12 patients receiving concomitant BTK inhibitors and either antiplatelet drugs or anticoagulation there were 2 cases of grade 2 bleeding." Mihailescu L, et al. The plymouth experience of bleeding complications associated with concomitant treatment with BTK inhibitors and anticoagulants or antiplatelet drugs. British Journal of Haematology 181 (Suppl. 1): 175 (plus poster) abstr. BSH18-EP-033, Apr 2018. Available from: URL: http://doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323365 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off